BiotechTube

Baricitinib 4 milligram Oral Tablet

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lichen Planus, Oral

Conditions

Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus

Trial Timeline

Mar 13, 2024 → Sep 1, 2026

NCT ID
NCT06158113

About Baricitinib 4 milligram Oral Tablet

Baricitinib 4 milligram Oral Tablet is a phase 2 stage product being developed by Eli Lilly for Lichen Planus, Oral. The current trial status is active. This product is registered under clinical trial identifier NCT06158113. Target conditions include Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06158113Phase 2Active

Competing Products

12 competing products in Lichen Planus, Oral

See all competitors
ProductCompanyStageHype Score
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Tacrolimus cream + Clobetasol creamAstellas PharmaPhase 2
52
pimecrolimus and clobetasol + clobetasol 0.05% creamNovartisPhase 2
52
Pimecrolimus 1% creamNovartisPhase 2
52
secukinumab 300 mg Q4W + secukinumab 300 mg Q2WNovartisPhase 2
52
Apremilast + PlaceboAmgenPhase 2
51
DeucravacitinibBristol Myers SquibbPhase 2
51
Dupilumab + PlaceboSanofiPhase 3
76
Dupilumab + PlaceboSanofiPhase 3
76
Amevive (Alefacept) + PlaceboBiogenPhase 2
49
Ruxolitinib cream + Vehicle creamIncytePhase 2
49
Ruxolitinib cream + Vehicle creamIncytePhase 2
49

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85